XML 61 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business Combination - Narratives (Details) - ARIAD Pharmaceuticals - USD ($)
$ in Millions
12 Months Ended
Jun. 01, 2016
Dec. 31, 2017
Dec. 31, 2016
Business combinations      
Upfront Payment $ 147.5    
Fair value of consideration transferred      
Fair value of consideration transferred 440.5    
Cash 147.5    
Contingent consideration $ 293.0    
Contingent Consideration      
Fair value of consideration transferred      
Probability of technical success (“PTS”) (as a percent) 25.00%    
Projected cash flows period 18 years    
Discount rate (as a percent) 10.00%    
Minimum      
Business combinations      
Royalties paid (as a percentage) 32.00%    
Maximum      
Business combinations      
Royalties paid (as a percentage) 50.00%    
Potential future oncology development and regulatory approval milestone payments $ 135.0    
Development costs   $ 7.0 $ 7.0